Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...

ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted ...

The class of cancer therapies known as antibody drug conjugates showed toxic drug payloads can be delivered to tumors in a targeted way. The first ADCs delivered chemotherapy, but the field is also ...

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...

An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead. That was one clear takeaway from the JPMorgan ...

QLi5 Therapeutics GmbH (QLi5), a spin-off from the Max Planck Institute for Biochemistry, has successfully completed a ...

B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively Deep and durable regressions ...